Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?
Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
Yip
G
G
Department of Medicine, Austin Health, Melbourne, Victoria, Australia. garyyip2001@yahoo.com.au
Ekinci
E
E
Lee
S T
ST
Jerums
G
G
Grossmann
M
M
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000175:diagnosis* / Q000276:immunology; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D002231:Carbimazole / Q000009:adverse effects; D005260:Female; D006801:Humans
D019268:Antibodies, Antineutrophil Cytoplasmic; D002231:Carbimazole